Literature DB >> 10645115

Life-saving treatments and disabilities. Are all QALYs created equal?

P A Ubel1, J Richardson, J L Prades.   

Abstract

OBJECTIVES: Decision-makers and the general public are often reluctant to adopt policy recommendations based exclusively upon cost-utility analyses. One possible reason explored here is that patients' previous health state before experiencing the onset of an acute life-threatening illness may influence the value of saving those patients' lives.
METHODS: We surveyed members of the general public to see the relative importance of saving patients' lives when some patients could be returned to perfect health and others would live the remainder of their years with paraplegia. Among this latter group, some were described as having pre-existing paraplegia. Others were described as having as having the onset of paraplegia. The relative importance of saving each of these lives was measured using the person trade-off method.
RESULTS: Six hundred five subjects completed questionnaires, and 250 met pre-established consistency criteria and were included in the final analysis. Overall, subjects placed equal importance on saving the lives of people with pre-existing paraplegia versus those who could be returned to perfect health because they did not have pre-existing paraplegia. In contrast, respondents gave lower priority to patients who would experience the onset of paraplegia after having their lives saved, especially if their paraplegia was avoidable with an alternative treatment.
CONCLUSION: People do not think that all quality-adjusted life-years are created equal. Instead, the value that people place on treatment programs depends on patients' state of health before developing life-threatening illnesses, and on whether alternative treatments are available that provide better health outcomes for the patients. These results may explain, in part, public discomfort over basing health care priorities on cost-utility analysis.

Entities:  

Keywords:  Empirical Approach; Health Care and Public Health

Mesh:

Year:  1999        PMID: 10645115

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  8 in total

Review 1.  Resource allocation, social values and the QALY: a review of the debate and empirical evidence.

Authors:  David L B Schwappach
Journal:  Health Expect       Date:  2002-09       Impact factor: 3.377

2.  QALYs: are they helpful to decision makers?

Authors:  Maurice McGregor; J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  Societal values in the allocation of healthcare resources: is it all about the health gain?

Authors:  Tania Stafinski; Devidas Menon; Deborah Marshall; Timothy Caulfield
Journal:  Patient       Date:  2011       Impact factor: 3.883

4.  The social value of a QALY: raising the bar or barring the raise?

Authors:  Cam Donaldson; Rachel Baker; Helen Mason; Michael Jones-Lee; Emily Lancsar; John Wildman; Ian Bateman; Graham Loomes; Angela Robinson; Robert Sugden; Jose Luis Pinto Prades; Mandy Ryan; Phil Shackley; Richard Smith
Journal:  BMC Health Serv Res       Date:  2011-01-11       Impact factor: 2.655

5.  Trading people versus trading time: what is the difference?

Authors:  Laura J Damschroder; Todd R Roberts; Christine C Goldstein; Molly E Miklosovic; Peter A Ubel
Journal:  Popul Health Metr       Date:  2005-11-10

6.  The equivalence of numbers: the social value of avoiding health decline: an experimental Web-based study.

Authors:  David L B Schwappach
Journal:  BMC Med Inform Decis Mak       Date:  2002-03-05       Impact factor: 2.796

7.  Value-based pricing of a COVID-19 vaccine.

Authors:  Afschin Gandjour
Journal:  Q Rev Econ Finance       Date:  2021-12-24

8.  The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany.

Authors:  Afschin Gandjour
Journal:  Q Rev Econ Finance       Date:  2020-10-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.